Nitric oxide in hypertension

Matthias Hermann1, Andreas Flammer, Thomas F Lüscher

  • 1Department of Cardiology, the Cardiovascular Center, University Hospital Zurich, Switzerland.

Insights

Endothelial dysfunction, marked by impaired nitric oxide (NO) bioavailability, is a key factor in hypertension and cardiovascular disease. Understanding NO

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Nephrology

Background:

  • Hypertension is a primary risk factor for cardiovascular disease.
  • Endothelial dysfunction, characterized by impaired nitric oxide (NO) bioavailability, links hypertension and cardiovascular disease.
  • NO plays a critical role in blood pressure regulation.

Purpose of the Study:

  • To explore the role of endothelial dysfunction and impaired NO bioavailability in hypertension.
  • To investigate the mechanisms linking NO bioactivity to blood pressure regulation.
  • To highlight the therapeutic implications of understanding NO mechanisms in hypertension.

Main Methods:

  • Review of evidence linking NO bioactivity to hypertension.
  • Analysis of genetic studies (e.g., endothelial NO synthase gene disruption in mice).
  • Examination of clinical studies on vasodilatory responses and NO inhibition in hypertensive patients.

Main Results:

  • Endothelial dysfunction and impaired NO bioavailability are significant contributors to hypertension.
  • Genetic models show elevated blood pressure with disrupted endothelial NO synthase.
  • Hypertensive patients exhibit blunted responses to vasodilators, and NO inhibition raises blood pressure.
  • Impaired NO bioactivity is associated with arterial stiffness and systolic hypertension.

Conclusions:

  • Impaired NO bioactivity is a crucial factor in the development and progression of hypertension.
  • Understanding the mechanisms of NO bioactivity impairment is vital for developing novel hypertension treatments.
  • Targeting NO pathways may offer new therapeutic strategies for managing hypertension and cardiovascular risk.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...